AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20110249
Drug: Flexible dosing
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible dosing of active vitamin D alone
Trial: 18427279
Drug: Pitavastatin 4
RxNorm normalized name: PITAVASTATIN 4MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 4 mg/d
Trial: 1854570
Drug: Diuretics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics plus enalapril or captopril (group 2)
Trial: 1854570
Drug: Diuretics alone
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics alone (group 1)
Trial: 6315227
Drug: Continuous chemotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous chemotherapy (1‐(2‐chloroethyl‐3‐cyclohexyl‐1‐nitrosourea, cyclophosphamide, methotrexate, and vincristine followed by 4'‐demethylepipodophyllotoxin 9‐[4,6‐O‐(R) ethylidene‐beta‐D‐glucopyranoside] and doxorubicin at progression of disease)
Trial: 6315227
Drug: Alternating chemotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemotherapy (alternating the same drugs as continuous)
Trial: 15759946
Drug: 3 MU
RxNorm normalized name: Orasep Reformulated Dec 2013 Mucosal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 MU daily interferon (IFN)‐alpha‐2a monotherapy for 12 months
Trial: 15759946
Drug: 6 MU
RxNorm normalized name: Pancrelipase 16 mu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 MU daily interferon (IFN)‐alpha‐2a monotherapy for 12 months
Trial: 10487369
Drug: Carbohydrate-electrolyte solution
RxNorm normalized name: CARBOHYDRATE/ELECTROLYTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-electrolyte solution (CHO-E)
Trial: 7729608
Drug: 6-h clamped
RxNorm normalized name: CLAMP,BAG H#7765
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-h clamped hyperglycemia (PG approximately 13.5 mmol/l)
Trial: 7729608
Drug: Nocturnal hyperglycemia
RxNorm normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nocturnal hyperglycemia (PG approximately 13.5 mmol/l)
Trial: 7729608
Drug: Euglycemia (PG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemia (PG approximately 5 mmol/l)
Trial: 7729608
Drug: 15 h
RxNorm normalized name: PEG-15 hydroxystearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 h of euglycemia (approximately 5 mmol/l)
Trial: 7729608
Drug: 15 h
RxNorm normalized name: PEG-15 hydroxystearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 h of hyperglycemia (approximately 17 mmol/l)
Trial: 30292850
Drug: Once-daily (OD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily (OD) PCI
Trial: 30292850
Drug: Twice-daily (BD)
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily (BD) PCI
Trial: 30292850
Drug: Delay between
RxNorm normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delay between end of chemotherapy and PCI
Trial: 29258763
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of intravenous dexamethasone and 1 dose of normal saline (Group B)
Trial: 29258763
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of intravenous dexamethasone (Group C)
Trial: 29258763
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of normal saline (Group A)
Trial: 26419487
Drug: Pregabalin and
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin and celecoxib combination
Trial: 25287827
Drug: Dabrafenib and
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib and trametinib (combination therapy)
Trial: 8933665
Drug: Anti-pertussis vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-pertussis vaccines
Trial: 1540362
Drug: Labetalol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (0.4 mg/kg)
Trial: 3546255
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral meclofenamate during the follicular phase
Trial: 3546255
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral meclofenamate during the luteal phase
Trial: 3546255
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg inhaled metaproterenol
Trial: 20078609
Drug: Sitaxentan 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitaxentan 100 mg daily for 7 days
Trial: 24656288
Drug: Sitaxentan 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitaxentan 100 mg
Trial: 17686882
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (E(2)) administration
Trial: 17686882
Drug: L-arginine/GHRP-2 stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine/GHRP-2 stimulation
Trial: 17686882
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (E(2))
Trial: 17686882
Drug: L-arginine/GHRH stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine/GHRH stimulation
Trial: 10580458
Drug: Rofecoxib (12.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (12.5, 25, or 50 mg/d)
Trial: 10580458
Drug: NSAIDs (ibuprofen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (ibuprofen, diclofenac, nabumetone)
Trial: 7825523
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acid supplementation (12 g fish oil)
Trial: 2328299
Drug: Diltiazem conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem conventional tablet (2 x 30 mg)
Trial: 2328299
Drug: Diltiazem slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem slow-release capsule (120 mg SR)
Trial: 438650
Drug: Bile acid
RxNorm normalized name: Bile acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bile acid mixture (cholic‐chenodeoxycholic 2:1, 20 mg/kg)
Trial: 438650
Drug: Sitosterol-bile acid
RxNorm normalized name: sitosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitosterol-bile acid mixture (bile acid mixture plus sitosterols, 200 mg/kg)
Trial: 15878048
Drug: Ecologically based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecologically based family therapy (EBFT)
Trial: 25887789
Drug: Elective laparoscopic
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective laparoscopic appendectomy plus maintenance treatment (5‐ASA)
Trial: 25887789
Drug: Maintenance 5‐ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance 5‐ASA treatment (no appendectomy)
Trial: 19338149
Drug: Shugan Liangxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shugan Liangxue Compound (SLC)
Trial: 2497647
Drug: 2.5 cm
RxNorm normalized name: NeuroMatrix, 2 mm IDx2.5 cm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 cm capsule (12 mg of levonorgestrel)
Trial: 2497647
Drug: 4.0 cm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 cm capsule (21.6 mg of levonorgestrel)
Trial: 7293937
Drug: Whole eggs
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole eggs (0.5 cup, approximately 500 mg cholesterol)
Trial: 30602311
Drug: Topical spironolactone
RxNorm normalized name: spironolactone Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical spironolactone
Trial: 28880750
Drug: Aqua-Lymphatic Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqua-Lymphatic Therapy (ALT), group sessions twice a week for 6 weeks
Trial: 28880750
Drug: Control group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group, group sessions twice a week for 6 weeks
Trial: 25541155
Drug: Age >55,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age >55, maximum grade of PN during docetaxel treatment, persistent muscle and joint pain, stomatitis, fatigue
Trial: 19122354
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg overnight dexamethasone suppression test
Trial: 19122354
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg overnight dexamethasone suppression test
Trial: 18082216
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (0.5 mg dutasteride + 0.4 mg tamsulosin)
Trial: 12364431
Drug: Oral Medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Medroxyprogesterone Acetate (MPA)
Trial: 12364431
Drug: Oral Micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Micronized Progesterone (MP)
Trial: 9250122
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg elemental Zn daily for 6 months)
Trial: 8099118
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment based upon weight reduction and recommendations about a low alcohol intake
Trial: 8099118
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment using a stepped-care approach with atenolol as the first-choice drug
Trial: 3828192
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg i.v. prochlorperazine
Trial: 3828192
Drug: 6.25 mg
RxNorm normalized name: captopril 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.25 mg i.v. prochlorperazine
Trial: 11333010
Drug: Telmisartan (angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (angiotensin II receptor antagonist)
Trial: 30648598
Drug: Oat noodles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat noodles (100 g, replacing one or two meals/day for 10 weeks)
Trial: 30145267
Drug: Standard rehabilitative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard rehabilitative care (physical and occupational therapy and psychoeducation)
Trial: 30145267
Drug: Complementary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary and integrative health therapies (chiropractic, acupuncture, yoga and psychoeducation)
Trial: 30145267
Drug: Alternative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative treatment (if initial treatment is not effective)
Trial: 30145267
Drug: First-stage treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-stage treatment plus the alternative treatment (if initial treatment is not effective)
Trial: 23038682
Drug: 7.47 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.47 g of intravenous methylprednisolone
Trial: 23038682
Drug: 4.98 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.98 g of intravenous methylprednisolone
Trial: 23038682
Drug: 2.25 g
RxNorm normalized name: Zosyn 2.25 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.25 g of intravenous methylprednisolone
Trial: 17376268
Drug: Thymosin-alpha1 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin-alpha1 1.6 mg by subcutaneous injection twice daily for 1 week
Trial: 17376268
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (broad-spectrum antibiotics only)
Trial: 11905433
Drug: Alcohol (social
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (social dose)
Trial: 2149688
Drug: Octreotide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (400 micrograms per day via continuous subcutaneous infusion)
Trial: 6992856
Drug: Topical oxytetracycline
RxNorm normalized name: oxytetracycline Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oxytetracycline oily suspension, twice daily for 7 days each month for 12 months
Trial: 6992856
Drug: Oral doxycycline
RxNorm normalized name: doxycycline Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxycycline 5 mg per kilogram of body weight, once a month for 12 months
Trial: 6992856
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received vitamin pills once a month
Trial: 28553847
Drug: Ezetimibe (EZE)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (EZE) 10 mg/day co-administered with atorvastatin 20 mg for 16 weeks
Trial: 28553847
Drug: Atorvastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin monotherapy (20 mg for 16 weeks)
Trial: 22940818
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) at doses of 6,000 or 12,000 IU administered intravenously within 6 hours after successful percutaneous coronary intervention (PCI)
Trial: 22940818
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously within 6 hours after successful percutaneous coronary intervention (PCI)
Trial: 19237568
Drug: MF59‐H5N1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59‐H5N1 vaccine
Trial: 19237568
Drug: Plain H5N1
RxNorm normalized name: influenza, H5N1-1203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain H5N1 vaccine
Trial: 17890472
Drug: Inhaled human
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled human insulin
Trial: 15890830
Drug: Unrestricted oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unrestricted oral carbohydrate intake during labor
Trial: 7524159
Drug: Paclitaxel (Taxol)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (Taxol) 3-hour infusion without G-CSF
Trial: 7524159
Drug: Paclitaxel (Taxol)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (Taxol) 3-hour infusion with G-CSF
Trial: 7524159
Drug: Paclitaxel (Taxol)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (Taxol) 3-hour infusion
Trial: 2895993
Drug: Clorazepate dipotassium
RxNorm normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorazepate dipotassium (15 to 60 mg/d)
Trial: 2895993
Drug: Buspirone hydrochloride
RxNorm normalized name: Buspirone Hydrochloride
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buspirone hydrochloride (10 to 40 mg/d)
Trial: 31628668
Drug: Rifampicin 150
RxNorm normalized name: Rifampicin 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 150 mg
Trial: 31628668
Drug: Rifampicin 300
RxNorm normalized name: Rifampicin 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 300 mg
Trial: 973984
Drug: Rifampicin 600
RxNorm normalized name: Rifampicin 600 mg powder for solution for infusion vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg
Trial: 31628668
Drug: Probe drug
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probe drug cocktail (atorvastatin, pitavastatin, rosuvastatin, valsartan)
Trial: 31078149
Drug: Humic acid
RxNorm normalized name: humic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humic acid (100 mg.L‐1) with CuO nanoparticles (various concentrations)
Trial: 31078149
Drug: Humic acid
RxNorm normalized name: humic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humic acid (100 mg.L‐1)
Trial: 28327379
Drug: Computer tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer tablet
Trial: 25288262
Drug: 2,790-nm resurfacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,790-nm resurfacing laser (double pass treatment at fluences less than or equal to 2.5 mJ with 10% overlap)
Trial: 25288262
Drug: 2,790-nm resurfacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,790-nm resurfacing laser (one pass treatment at fluences greater than or equal to 3.0 mJ with 10% overlap)
Trial: 23982575
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor physical therapy (PFPT) 2 weeks preoperatively and 2, 4, 6, 8, and 12 weeks postoperatively
Trial: 21762357
Drug: Telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 mg/Amlodipine 5 mg (T40/A5)
Trial: 24391142
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg/Amlodipine 5 mg (T80/A5)
Trial: 22853848
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg (A5)
Trial: 22853848
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg (A10)
Trial: 19092234
Drug: NPPV plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPPV plus usual dosage of oxygen
Trial: 19092234
Drug: Usual dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual dosage of oxygen
Trial: 14574511
Drug: Scintigraphic evaluation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scintigraphic evaluation using 5, 10, 15, and 20 ml of water containing 0.5 mCi technetium‐99m labelled sulphur colloid
Trial: 8784560
Drug: Prior antibiotic
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior antibiotic treatment
Trial: 1472394
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group with initial cholesterol level of 6.50 mmol l‐1 or greater.
Trial: 1472394
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group with initial cholesterol level of less than 5.20 mmol l‐1.
Trial: 19701237
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg clarithromycin tablets twice a day for 4 days
Trial: 19701237
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 4 days
Trial: 17590156
Drug: Sub-antimicrobial dose
RxNorm normalized name: DAB(SUB 389)IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-antimicrobial dose doxycycline (SDD)
Trial: 6704545
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with weekly cytosine arabinoside and 6‐thioguanine alone (69 patients)
Trial: 6704545
Drug: Two courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two courses of reduced doses of DAT 1 month apart followed by the same maintenance program (77 patients)
Trial: 26752653
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose clazosentan (15 mg/h)
Trial: 22835570
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) applied twice on the cervical erosion with a 1-week interval
Trial: 8911108
Drug: Alternating chemotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemotherapy (VIMP) - vincristine, carboplatin, ifosfamide, mesna
Trial: 8911108
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (CDE) - cyclophosphamide, doxorubicin, etoposide
Trial: 1651434
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (one injection daily)
Trial: 1651434
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low molecular weight heparin + dihydroergotamine (one injection daily)
Trial: 1651434
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (3 applications of 5000 IU per day)
Trial: 1651434
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Low molecular weight heparin alone)